Navigation Links
FDA Gives Approval for Skin Cancer Drug, Zolinza

Zolinza, the most recent skin cancer drug has today received approval from the U.S. Food and Drug Administration (FDA). Zolinza (vorinostat) capsules is mainly recommended// for the treatment of cutaneous T-cell lymphoma (CTCL) type of skin cancer when the disease persists, worsens, or returns during or after treatment with other medicines.

Zolinza has been approved as part of FDA's Orphan Drug program that offers companies financial incentives to develop medications for diseases which affect less than 200,000 American patients a year. About three in every one million people are diagnosed with CTCL each year in the United States. Most of those afflicted with CTCL are men with an average age of 50 years.

Steven Galson, M.D., director of FDA's Center for Drug Evaluation and Research said, "This approval is another example of the benefits of modern research that's focused on providing prescribers with safe and effective therapies for all types of cancer, including those that affect relatively few patients."

Two clinical trials that were conducted with 107 CTCL patients gave evidence of Zolinza's safety and effectiveness. These patients were treated with Zolinza following return of their disease following other treatments.

30 percent of patients who received Zolinza observed an improvement in a scale that was defined by scoring of skin lesions and lasted an average of 168 days.

Some of the most common serious adverse events that occurred were pulmonary embolism, deep vein thrombosis, dehydration, and anemia. Some of most common other adverse events were gastrointestinal symptoms such as nausea, diarrhea, vomiting, anorexia and constipation; fatigue; chills; and taste disorders.

However Zolinza has shown probable fetal harm if administered during pregnancy according to results of animal studies.

Zolinza is manufactured by Pantheon, Inc., in Mississauga, Ontario, Canada, for Merck & Co., Inc., Whitehouse Station, N.J.
NLA
'"/>




Related medicine news :

1. Groundbreaking Study Gives Hope For Patients With Kidney Cancer
2. Gene Therapy Gives Hope For Patients With Muscular Dystrophy
3. Statins Gives New Hope for Increased Survival Rate of Heart Failure Patients
4. US Doctors Association Gives away $110,000 To NGO’
5. Woman In Coma Gives Birth To Daughter
6. Artificial Heart , Gives Hope For Patients Awaiting a Heart Transplant
7. New Eye Surgery Gives Hope To Short-Sighted
8. Jharkhand Gives Health industry status
9. WHO Gives Its Approval For Bird Flu Test Kit
10. FDA Gives Its Approval For Inhaler
11. Congestion for Use of Clarinex-D 12 Hour cleared – FDA Gives the No
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/31/2016)... ... May 31, 2016 , ... Interest is on the rise for ... as an orthogonal tool for RNAi hit validation. A key reason may be that ... rapid generation of CRISPR RNA (crRNA) collections in arrayed formats. , Arrayed ...
(Date:5/31/2016)... ... 31, 2016 , ... In a recent interview on The Greenburgh Report radio ... NY-based WVOX (1460 AM), leading medical insurance advocate Adria Goldman Gross discussed ... medical money maelstrom.” , During the interview with Mr. Feiner that aired on ...
(Date:5/31/2016)... ... May 31, 2016 , ... Advertising ... firm and statement solutions provider, for the tenth consecutive year as a Top ... of Advertising Age, and SourceLink ranked eighteenth in the “U.S. CRM/Direct Marketing Agency” ...
(Date:5/31/2016)... Port Washington, NY (PRWEB) , ... May 31, 2016 , ... ... and other essential nutrients to on the go individuals and dedicated athletes, continues to ... functions. , Loaded with whey, pea and milk protein, branched-chain amino acids (BCAA), ...
(Date:5/30/2016)... ... May 30, 2016 , ... ... announced today the publication of an original infographic, " Health Benefits Reimbursement Compliance ... professionals understand how Zane Benefits complies with various federal regulations and reforms. , ...
Breaking Medicine News(10 mins):
(Date:5/31/2016)... May 31, 2016 RnRMarketResearch.com adds ... with comparative analysis of Asthma therapy at various stages, ... route of administration (RoA) and molecule type, along with ... also reviews key players involved in the therapeutic development ... projects. Complete report on H1 2016 pipeline ...
(Date:5/30/2016)... On 28 May, 194 Member States made a historic ... th World Health Assembly, governments unanimously voted to adopt ... global commitment in viral hepatitis to date. The ... by 2030 and includes a set of prevention and treatment ... and increase treatment to 80%, saving 7.1 million lives globally ...
(Date:5/27/2016)... Israel , May 27, 2016 ... of the Dario™ Diabetes Management Tool, today announced that the ... at the Marcum MicroCap Conference being held June 1-2 in ... Micro Invitational, being held June 7-9 in Los ... Ben-David will discuss recent corporate and operational milestones, including the ...
Breaking Medicine Technology: